Duchenne Muscular Dystrophy (DMD) impacts millions globally, necessitating a robust market for effective treatments. The current DMD treatment landscape is characterized by the focus on symptom management and supportive care. However, recent advances in gene therapy and medications are paving the way for potential curative treatments. Studies are